Gilead Sciences, Inc. (NASDAQ:GILD) New HIV Tablet Shows Better Potential Than Already Approved Stribild

Albany, New York (09/25/2014) – Gilead Sciences, Inc. (NASDAQ:GILD) is working at present, on its new HIV tablet, which contains tenofovir alafenamide. The company has already conducted two studies with the middle stage. Recently, Gilead said that the newly tested tablet gave better results than the already approved drug, Stribild, in two studies at mid-stage.

New HIV Drug better than Approved Stribild

It was found that 93% patients, who took the tenofovir alafenamide-containing drug, showed reduced level of HIV virus in the blood, in its first stage of study. In comparison, the FDA-approved Stribild does the same in 92% of the patients. The second research study, it was found that 91.6% patients showed reduced HIV virus level in blood, in contrast with 88% of the patients taking Stribild.

The Financial Aspect

The analysts at RBC Capital Markets say that this was a positive sign for Gilead Sciences, Inc. (NASDAQ:GILD) because it led to an increase in the confidence of the company’s enduring revenue potential. This potential, the analysts said, will be tapped from HIV drug pipeline, even after 2018.

In context with the revenue, it is expected that Gilead will gross and increase to $11.7 billion in 2018 from just HIV drugs. The analysts at Morningstar said that there are 70% chances of this HIV drug with tenofovir alafenamide getting approval from the USFDA.

Approval beyond the U.S.

Gilead Sciences will seek approval from the FDA for this new HIV tablet in the fourth quarter of the present financial year. Also, the company is planning apply for the approval from the European regulatory for the same drug. In a separate story, Gilead Sciences said that it has already filed for the approval from Japan for its treatment concerning Hepatitis C.

Approximately 35 million people across the world are suffering from HIV and around 11.7 million people living in the developing countries are receiving the therapies for HIV. Interestingly, Gilead Sciences, Inc. (NASDAQ:GILD) reaches 125 countries in the world for the treatment of HIV and these countries are the abode to approximately 95% people having HIV. Maximum number of these countries is developing.

About the Author

Laurie, a long-time member of the US Markets Daily general assignment reporter who has covered a variety of subjects from breaking news to investigative features, from stock markets to politics, and from neighborhood small business to global warming.

Leave A Response